Pfizer Investor Presentation — March 2022

Document content

Truist Securities Life

Sciences AI Symposium –

Forward Looking Statements and Other Notices

This presentation may include forward -looking statements about, among other topics, Pfizer's digital strategy; our efforts to

respond to COVID -19, including Comirnaty and Paxlovid ; the development or commercial potential of our product pipeline,

in-line products, product candidates and additional indications; our anticipated future operating and financial performance,

business plans and prospects; our ability to successfully capitalize on growth opportunities and prospects; and other

statements about our business, operations and financial results that are each subject to substantial risks and uncertainties

that could cause actual results to differ materially from those expressed or implied by such statements. These statements

are subject to risks, uncertainties and other factors that may cause actual results to differ materially from past results, future

plans and projected future results.

Additional information regarding these and other factors can be found in Pfizer’s Annual Report on Form 10 -K for the fiscal

year ended December 31, 2021 and in our subsequent reports on Form 10 -Q, including in the sections thereof captioned

“Risk Factors” and “Forward -Looking Information and Factors That May Affect Future Results”, as well as in our subsequent

reports on Form 8 -K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov

and www.pfizer.com .

Potential risks and uncertainties also include the impact of COVID -19 on our sales and operations, including impacts on

employees, manufacturing, supply chain, research and development, and clinical trials. The forward -looking statements in